Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

Phase 4

Terminated

Conditions: Regional Anesthesia Morbidity
Anticoagulants and Bleeding Disorders
Surgery

Interventions: Drug: Enoxaparin

First Posted Date: 2017-09-28

Last Posted Date: 2023-10-05

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 122

Registration Number: NCT03296033

Locations: 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Phase 2

Completed

Conditions: Knee Arthroplasty, Total

Interventions: Drug: BAY1213790
Drug: Enoxaparin
Drug: Apixaban

First Posted Date: 2017-09-08

Last Posted Date: 2020-03-03

Lead Sponsor: Bayer

Target Recruit Count: 813

Registration Number: NCT03276143

Locations: 🇱🇹
Republican Vilnius University Hospital, Vilnius, Lithuania
🇵🇱
Wojewódzki Szpital Zespolony, Kielce, Poland
🇵🇱
Szpital Specjalistyczny im. Rydygiera, Krakow, Poland

and more 51 locations

Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD

Not Applicable

Conditions: Acute Exacerbation Copd
Venous Thromboembolism

Interventions: Drug: Enoxaparin
Drug: Rivaroxaban

First Posted Date: 2017-09-08

Last Posted Date: 2017-09-08

Lead Sponsor: Huashan Hospital

Target Recruit Count: 438

Registration Number: NCT03277001

Locations: 🇨🇳
Huashan hospital,Fudan university, Shanghai, Shanghai, China

Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

Phase 2

Conditions: Esophageal Neoplasms

Interventions: Drug: Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable
Radiation: Radiotherapy
Drug: Chemotherapeutic Combinations

First Posted Date: 2017-08-18

Last Posted Date: 2017-08-22

Lead Sponsor: Mashhad University of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT03254511

Locations: 🇮🇷
Mashhad University of Medical Sciences, Mashhad, Khorasan Razavi, Iran, Islamic Republic of

Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

Phase 2

Completed

Conditions: Venous Thromboembolism
Deep Venous Thrombosis
Surgery

Interventions: Drug: Fixed Dose Enoxaparin
Drug: Variable Dose Enoxaparin

First Posted Date: 2017-08-16

Last Posted Date: 2020-07-08

Lead Sponsor: University of Utah

Target Recruit Count: 131

Registration Number: NCT03251963

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

LMWH Vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

Phase 4

Conditions: Bone Metastases
Soft Tissue Sarcoma
Bone Sarcoma
Hematoma
Anticoagulant-induced Bleeding
Sarcoma
Venous Thromboembolism

Interventions: Drug: Enoxaparin 40Mg/0.4mL Prefilled Syringe
Drug: Aspirin 325mg

First Posted Date: 2017-08-09

Last Posted Date: 2024-12-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 2868

Registration Number: NCT03244020

Locations: 🇺🇸
University of California Los Angeles Health, Los Angeles, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Louisiana State University Health, New Orleans, Louisiana, United States

and more 7 locations

Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function

Phase 4

Completed

Conditions: Renal Impairment
Venous Thromboembolism

Interventions: Drug: Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
Drug: Enoxaparin 20Mg/0.2mL Prefilled Syringe

First Posted Date: 2017-05-18

Last Posted Date: 2017-09-11

Lead Sponsor: Lebanese American University

Target Recruit Count: 32

Registration Number: NCT03158792

Locations: 🇱🇧
LAU Medical Center-Rizk Hospital, Beirut, Lebanon

Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study

Phase 4

Completed

Conditions: Primary Percutaneous Coronary Intervention

Interventions: Drug: Enoxaparin

First Posted Date: 2017-05-10

Last Posted Date: 2018-04-19

Lead Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 22

Registration Number: NCT03146858

Locations: 🇬🇧
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom

Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)

Phase 4

Completed

Conditions: Percutaneous Coronary Intervention
Coronary Artery Disease

Interventions: Drug: Enoxaparin (Standard-dose Group)
Drug: Enoxaparin (Staged-dose PCI Group)
Drug: Enoxaparin (High-dose Group)
Drug: Enoxaparin (Single-dose PCI Group)

First Posted Date: 2017-05-09

Last Posted Date: 2022-10-12

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 378

Registration Number: NCT03145675

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement

Phase 2

Completed

Conditions: Total Knee Replacement

Interventions: Drug: TeaRx
Drug: Enoxaparin

First Posted Date: 2017-03-23

Last Posted Date: 2017-03-23

Lead Sponsor: TeaRx LLC

Target Recruit Count: 200

Registration Number: NCT03088358

Locations: 🇷🇺
St. Petersburg State Institution of Health "City Hospital № 2", Saint Petersburg, Russian Federation
🇷🇺
SHI of the city of Moscow City Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation
🇷🇺
SHAI "Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan", Kazan, Russian Federation

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy